Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2014 Jul;19(3):192-8.

Evaluation of the efficacy and safety of pregabalin, venlafaxine, and carbamazepine in patients with painful diabetic peripheral neuropathy. A randomized, double-blind trial

Nazanin Razazian  1 , Maryam Baziyar, Nasrin Moradian, Daryoush Afshari, Arash Bostani, Marziyeh Mahmoodi
Affiliations
Randomized Controlled Trial

Evaluation of the efficacy and safety of pregabalin, venlafaxine, and carbamazepine in patients with painful diabetic peripheral neuropathy. A randomized, double-blind trial

Nazanin Razazian et al. Neurosciences (Riyadh). 2014 Jul.

Abstract

Objective: To evaluate the efficacy and safety of carbamazepine, pregabalin, and venlafaxine in patients with painful diabetic neuropathy (PDN).

Methods: Our study was performed as a randomized, double-blind, parallel-group clinical trial between December 2012 and December 2013 at Kermanshah University of Medical Sciences, Kermanshah, Iran. Two hundred and fifty-seven patients with clinically definite PDN were randomized to receive, carbamazepine, venlafaxine, or pregabalin. The primary outcome was subjective pain as assessed by the visual analogue scale (VAS). Secondary outcomes consisted of sleep, mood, and work interference assessments, and a percentage of patients achieving at least 50% reduction in pain intensity.

Results: Means of VAS scores for carbamazepine, pregabalin, and venlafaxine treatment groups at the baseline (74.5, 82.3, and 74.5) and endpoint (39.6, 33.4, and 46.6) revealed significant reduction, although pregabalin was more efficacious than carbamazepine, and venlafaxine. Improvements in means scores of sleep, mood, and work interferences were identified in all treatment groups.

Conclusion: This study showed the efficacy of venlafaxine, pregabalin, and carbamazepine in pain reduction in patients with diabetic neuropathy, although pregabalin was shown to be superior to carbamazepine, and venlafaxine in relieving pain, no significant superiority was shown between carbamazepine, and venlafaxine.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Distribution of diabetic peripheral neuropathy patients. Ec/MoH - European Commission/Ministry of Health
Figure 2
Figure 2
Comparisons of pain severity scores (VAS) between the treatment groups across time among diabetic peripheral neuropathy patients.
Figure 3
Figure 3
Change in pain severity in the treatment groups among diabetic peripheral neuropathy patients. Improved and worse categories includes cases with VAS reduction and increase. VAS - visual analogue scale
See this image and copyright information in PMC

References

    1. Apfel SC, Asbury AK, Bril V, Burns TM, Campbell JN, Chalk CH, et al. Positive neuropathic sensory symptoms as endpoints in diabetic neuropathy trials. J Neurol Sci. 2001;189:3–5. - PubMed
    1. Abbott CA, Malik RA, van Ross ER, Kulkarni J, Boulton AJ. Prevalence and characteristics of painful diabetic neuropathy in a large community-based diabetic population in the U.K. Diabetes Care. 2011;34:2220–2224. - PMC - PubMed
    1. Davies M, Brophy S, Williams R, Taylor A. The prevalence, severity, and impact of painful diabetic peripheral neuropathy in type 2 diabetes. Diabetes Care. 2006;29:1518–1522. - PubMed
    1. Backonja MM, Serra J. Pharmacological management part 1: better-studied neuropathic pain diseases. Pain Med. 2004;5(Suppl 1):28–47. Review. - PubMed
    1. Boulton AJ, Vinik AI, Arezzo JC, Bril V, Feldman EL, Freedman R, et al. Diabetic neuropathies: a statement by the American Diabetes Association. Diabetes Care. 2005;28:956–962. - PubMed

Publication types

MeSH terms